Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Naoki Hama

Showing results (141-150 of 151) with videos related to

Pageof 16
Sort By:
Transplantation Direct|December 20, 2016
Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein MicroarrayKeita Okubo, Hiroshi Wada, Atsushi Tanaka, et al.
Surgical Case Reports|October 23, 2024
An aggressive gastric CIC-DUX4 sarcoma surgically resected with multivisceral organs: a case reportMizuki Koba, Atsushi Takeno, Hiroko Hasegawa, et al.
The Journal of Biological Chemistry|July 12, 2014
Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell lineSakae Maeda, Hiroshi Wada, Yoko Naito, et al.
International Immunology|December 24, 2019
Interleukin-34 expression in ovarian cancer: a possible correlation with disease progressionHiraku Endo, Naoki Hama, Muhammad Baghdadi, et al.
Clinical Journal of Gastroenterology|March 10, 2021
Retrograde endoscopic submucosal dissection for early thoracic esophageal carcinomaYuta Kobayashi, Kazuhiro Nishikawa, Tomofumi Akasaka, et al.
Oncology Letters|January 2, 2016
Cyclin G2: A novel independent prognostic marker in pancreatic cancerShinichiro Hasegawa, Hiroaki Nagano, Masamitsu Konno, et al.
Trials|August 27, 2021
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)Daisaku Yamada, Shogo Kobayashi, Hidenori Takahashi, et al.
Plos One|March 26, 2026
Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027)Yoshito Tomimaru, Hirofumi Akita, Keisuke Tamari, et al.
Pancreas|July 25, 2014
Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic CancerKenta Furukawa, Koichi Kawamoto, Hidetoshi Eguchi, et al.
Internal Medicine (Tokyo, Japan)|April 3, 2015
Solitary fibrous tumor of the liver from development to resectionYuki Makino, Masanori Miyazaki, Minoru Shigekawa, et al.
Pageof 16

Showing results (141-150 of 151) with videos related to

Sort By:
Pageof 16
Transplantation Direct|December 20, 2016
Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein MicroarrayKeita Okubo, Hiroshi Wada, Atsushi Tanaka, et al.
Surgical Case Reports|October 23, 2024
An aggressive gastric CIC-DUX4 sarcoma surgically resected with multivisceral organs: a case reportMizuki Koba, Atsushi Takeno, Hiroko Hasegawa, et al.
The Journal of Biological Chemistry|July 12, 2014
Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell lineSakae Maeda, Hiroshi Wada, Yoko Naito, et al.
International Immunology|December 24, 2019
Interleukin-34 expression in ovarian cancer: a possible correlation with disease progressionHiraku Endo, Naoki Hama, Muhammad Baghdadi, et al.
Clinical Journal of Gastroenterology|March 10, 2021
Retrograde endoscopic submucosal dissection for early thoracic esophageal carcinomaYuta Kobayashi, Kazuhiro Nishikawa, Tomofumi Akasaka, et al.
Oncology Letters|January 2, 2016
Cyclin G2: A novel independent prognostic marker in pancreatic cancerShinichiro Hasegawa, Hiroaki Nagano, Masamitsu Konno, et al.
Trials|August 27, 2021
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015)Daisaku Yamada, Shogo Kobayashi, Hidenori Takahashi, et al.
Plos One|March 26, 2026
Study protocol: A randomized controlled trial of chemoradiotherapy versus chemotherapy as neoadjuvant therapy for resectable pancreatic cancer (CSGO-HBP-027)Yoshito Tomimaru, Hirofumi Akita, Keisuke Tamari, et al.
Pancreas|July 25, 2014
Clinicopathological Significance of Leucine-Rich α2-Glycoprotein-1 in Sera of Patients With Pancreatic CancerKenta Furukawa, Koichi Kawamoto, Hidetoshi Eguchi, et al.
Internal Medicine (Tokyo, Japan)|April 3, 2015
Solitary fibrous tumor of the liver from development to resectionYuki Makino, Masanori Miyazaki, Minoru Shigekawa, et al.
Pageof 16